Skip to main content

Table 1 Clinical characteristics and treatments - Crohn’s disease patients at the time of study inclusion. Values are given as the mean (minimum-maximum) for continuous variables and numbers (%) for categorical variables

From: Activation of the prostaglandin D2 metabolic pathway in Crohn’s disease: involvement of the enteric nervous system

  Quiescent Crohn’s disease Active Crohn’s disease Controls
Cases 15 15 15
Age, years 36 (18–63) 37 (21–76) 55 (38–76)
Sex female/male 9/8 11/4 4/11
Age at diagnosis, years 30 (19–60) 26 (15–58)  
Duration of the disease, years 7 (1–21) 12 (1–26)  
Current treatment    
No medication 1 (7 %) 5 (33 %)  
5-ASA/Salazopyrin/Azathioprine 2 (17 %) 2 (17 %)  
Corticosteroids/immunosuppressants 9 (60 %) 6 (40 %)  
Infliximab 8 (53 %) 5 (33 %)  
\